Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review

被引:7
作者
Ercan, Eyup Sabri [1 ]
Ardic, Ulku Akyol [1 ]
Basay, Burge Kabukcu [1 ]
Ercan, Elif [2 ]
Basay, Omer [1 ]
机构
[1] Ege Univ, Fac Med, Dept Child & Adolescent Psychiat, Izmir, Turkey
[2] Ege Univ, Fac Med, Dept Psychol Counseling & Guidance, Izmir, Turkey
关键词
ADHD; Atomoxetine; ADHD/I; ADHD/HI;
D O I
10.1007/s12402-013-0111-0
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, 1994, American Psychiatric Association) describes attention deficit hyperactivity disorder (ADHD) as a heterogeneous disorder; providing diagnostic criteria for three subtypes: hyperactive/impulsive (ADHD/HI), inattentive (ADHD/I), and combined type (ADHD/C). Differences among the subtypes are well defined, but there may be also differences in terms of treatment responses. The aim of this study is to assess the responses of ADHD/I and ADHD/C to atomoxetine treatment. The medical records of the January-June 2012 term, first time referrals to outpatient clinic, were reviewed, and 37 ADHD diagnosed primary school age children (18 ADHD/I, 19 ADHD/C) that were treated with atomoxetine were determined. Thirty-five of them who completed 8 weeks of treatment duration were recruited for the study. The children with an ADHD medication use history in 2 months time prior to onset of treatment and/or the children receiving additional psychopharmacologic treatment to atomoxetine were excluded. Baseline and eighth week assessment, records were evaluated. Efficacy assessments included Turgay DSM-IV ADHD Screening and Rating Scale parent and teacher forms (T-DSM-IV) and Clinical Global Impression Scale-Severity and Improvement subscales. Safety assessments included laboratory and body weight assessments, ECG, heart rate, and blood pressure evaluations (baseline and eighth week) along a scale filled by the parents at the eighth week to review side effects. Atomoxetine was found to be effective in both ADHD/I and ADHD/C groups. Atomoxetine also decreased the opposition defiance subscale scores of T-DSM-IV (both parent and teacher forms), whereas it was not found to make statistically significant difference in the conduct disorder subscale scores. Mean difference in 8-week time in T-DSM-IV hyperactivity subscale and total scores of parent and teacher forms; inattention subscale scores of only parent forms and the CGI-severity subscale scores; differed significantly among the ADHD/I and ADHD/C groups; that ADHD/C types responded better to medication. Results of this study revealed that atomoxetine is effective both in ADHD/I and ADHD/C subtypes. ADHD/C types may be responding better to atomoxetine treatment than the ADHD/I subtypes.
引用
收藏
页码:377 / 385
页数:9
相关论文
共 24 条
  • [1] American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596
  • [2] Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis
    Cheng, Jackie Y. W.
    Chen, Ronald Y. L.
    Ko, John S. N.
    Ng, Emil M. L.
    [J]. PSYCHOPHARMACOLOGY, 2007, 194 (02) : 197 - 209
  • [3] Response style differences in the inattentive and combined subtypes of attention-deficit/hyperactivity disorder
    Derefinko, Karen J.
    Adams, Zachary W.
    Milich, Richard
    Fillmore, Mark T.
    Lorch, Elizabeth P.
    Lynam, Donald R.
    [J]. JOURNAL OF ABNORMAL CHILD PSYCHOLOGY, 2008, 36 (05) : 745 - 758
  • [4] Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: Analysis of Canadian open-label studies
    Dickson R.A.
    Maki E.
    Gibbins C.
    Gutkin S.W.
    Turgay A.
    Weiss M.D.
    [J]. Child and Adolescent Psychiatry and Mental Health, 5 (1)
  • [5] Ercan ES, 2001, TURK J CHILD ADOLESC, V8, P132
  • [6] Gokler B, 2004, J CHILD ADOLESCENT M, V11, P3
  • [7] Guy W., 1976, DHEW PUBL, P218
  • [8] Schedule for Affective Disorders and Schizophrenia for School-Age Children Present and Lifetime version (K-SADS-PL): Initial reliability and validity data
    Kaufman, J
    Birmaher, B
    Brent, D
    Rao, U
    Flynn, C
    Moreci, P
    Williamson, D
    Ryan, N
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1997, 36 (07) : 980 - 988
  • [9] Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial
    Kelsey, DK
    Sumner, CR
    Casat, CD
    Coury, DL
    Quintana, H
    Saylor, KE
    Sutton, VK
    Gonzales, J
    Malcolm, SK
    Schuh, KJ
    Allen, AJ
    [J]. PEDIATRICS, 2004, 114 (01) : E1 - E8
  • [10] Acute atomoxetine treatment of younger and older children with ADHD: A meta-analysis of tolerability and efficacy
    Kratochvil C.J.
    Milton D.R.
    Vaughan B.S.
    Greenhill L.L.
    [J]. Child and Adolescent Psychiatry and Mental Health, 2 (1)